Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Circadian clock genes may provide targets for new cancer drugs

19.11.2003


Critical innovations and new knowledge are now emerging from the laboratories of universities, medical centers and pharmaceutical companies worldwide, offering the prospect of a new generation of drugs capable of destroying cancer cells with pinpoint accuracy, without damaging adjacent normal cells.

Each year, the American Association for Cancer Research (AACR), jointly with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC), brings together scientists and other professionals from around the world seeking to share the latest information in this field, otherwise known as molecular targets of cancer.

More than 2,500 scientists and clinicians – including top executives and researchers from more than 300 pharmaceutical and biotech companies – are gathering in Boston next week at the annual AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to present, discuss and hear about such promising discoveries as:



• The Circadian Rhythm of Cells, in which the “clock genes” that coordinate many fundamental cell functions operate according to a diurnal schedule. Researchers have hypothesized that cancer often occurs when the timing of circadian clock genes is “off,” resulting in an imbalance between cell proliferation and cell death. They believe these genes and their products represent novel targets for the control of cancer growth.

• Turning Tumors Against Themselves, by transforming the vascular endothelial growth factor (VEGF) from a promoter of angiogenic growth and survival to a cancer killer. One study shows that binding VEGF to the Fas apoptosis receptor, creating VEGFR2Fas, triggers the signal for cell death. Further investigation will seek to optimize this effect and determine the feasibility of using it in vivo to kill tumor cells and/or the blood vessels that fuel them directly.

• Improving the Effectiveness of Radiotherapy for some types of head and neck cancer by examining the biological profiles of different tumors, which affect their responsiveness to radiotherapy. Scientists hope eventually to be able to tailor cancer therapy specifically to the biological behavior of an individual patient’s tumor.

“This is the foremost annual meeting in drug development, coming at one of the most exciting times in the history of cancer research,” said AACR President Karen S. H. Antman, M.D., Wu Professor of Medicine and Professor of Pharmacology, Division of Oncology, Department of Medicine, Columbia University, New York.

“We have developed a number of new anti-cancer agents and identified potential targets. This meeting brings together everyone in the field to talk about strategies for evaluating these findings and taking them efficiently to the next step – to patients in clinical trials,” she added.

Meeting Scientific Chairman Charles L. Sawyers, M.D., Investigator and Professor in the Division of Hematology/Oncology at the David Geffen School of Medicine, University of California, Los Angeles, echoed the objective, saying:

“We are at a time in cancer research, both basic and clinical, when we understand some of the molecular lesions that drive cancer. We have a nice set of drug-like molecules either available or in development, but there is a disconnect between work in the laboratory and testing in patients. Right now the molecular profile of cancer is hard to recognize in patients, because it is not part of clinical trials nor the way cancer is classified. We need a consensus of opinion to bridge the gap between the lab and the patient.”

Target selection and barriers to the clinical testing of targeted agents will be debated by academic and pharmaceutical company scientists and federal regulators at two forums during the meeting.

Leroy E. Hood, Co-founder and President of the Institute for Systems Biology and Affiliate Professor at the University of Washington, both in Seattle, will give a keynote address on “Systems Biology and Cancer.” Dr. Hood is recognized as one of the world’s leading scientists in molecular biotechnology and genomics, and has applied his laboratory expertise in DNA sequencing to the analysis of human and mouse immune receptors, and initiated studies in prostate cancer, autoimmunity, and hematopoietic stem cell development.

Alex Matter of Novartis Pharma AG in Basel, Switzerland, will offer the second keynote speech, “The Reality of Making Cancer Drugs.” Dr. Matter and his team of 300 scientists were among the leaders in the discovery of Gleevec, the first oral drug shown to be effective in the treatment of chronic myeloid leukemia (CML).

For 20 years prior to 1999, NCI and EORTC held the conferences on cancer therapeutics biennially. Since then they have been held annually in conjunction with AACR, alternating venues between the United States and Europe. Next year’s meeting will be Sept. 28-Oct. 1, in Geneva, Switzerland.


Founded in 1907, the American Association for Cancer Research is a professional society of more than 21,000 laboratory, translational, and clinical scientists engaged in cancer research in the United States and in more than 60 other countries. AACR’s mission is to accelerate the prevention and cure of cancer through research, education, communication, and advocacy. This work is carried out through five major peer-reviewed scientific journals and high-quality scientific programs focusing on the latest developments in all areas of cancer research.

The National Cancer Institute, founded in 1971, is the principal United States government agency charged with coordinating the National Cancer Program. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.

The European Organisation for Research and Treatment of Cancer was organized in 1962 to conduct, develop, coordinate and stimulate laboratory and clinical research in Europe, and to improve the management of cancer and related problems by increasing the survival and quality of life for patients.

Warren Froelich | AACS
Further information:
http://www.aacr.org/1132at.asp

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>